Services was DarioHealth’s largest product and service line in fiscal 2025, bringing in $14.93M of $22.36M (67%).
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Consumers | — | — | — | ||||
| Services | $13.08M | $20.20M | $14.93M | ||||
| Service | — | — | — | ||||
| Hardware & Consumable Products | $7.27M | $6.84M | $7.43M | ||||
| Products | — | — | — | ||||
| Product | — | — | — | ||||
| Commercial | — | — | — | ||||
| Total | $20.35M | $27.04M | $22.36M |
DarioHealth brought in $22.36M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 17.3% from $27.04M in fiscal 2024. Services was the largest at $14.93M (66.8%), ahead of Hardware & Consumable Products at $7.43M (33.2%).
Compared with fiscal 2024, Hardware & Consumable Products grew 8.6% to $7.43M, while Services fell 26.1% to $14.93M. From fiscal 2023 to 2025, combined revenue from these lines grew from $20.35M to $22.36M, a compound annual growth rate of 4.8%. Services' share of the total rose from 64.3% to 66.8%.
Commercial - B2B2C was DarioHealth’s largest revenue line in fiscal 2025, bringing in $14.28M of $22.36M (64%).
| Contract with Customer, Sales Channel | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Commercial - B2B2C | — | $20.02M | $14.28M |
| Commercial - Business-To-Business-To-Consumer ("B2B2C") | $5.01M | — | — |
| Consumers | $8.29M | $7.53M | $8.08M |
| Commercial - Strategic Partnerships | $7.05M | -$514.00K | — |
| Total | $20.35M | $27.04M | $22.36M |
DarioHealth brought in $22.36M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. DarioHealth regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $27.04M. Commercial - B2B2C was the largest at $14.28M (63.9%), ahead of Consumers at $8.08M (36.1%).
Compared with fiscal 2024, Consumers grew 7.3% to $8.08M, while Commercial - B2B2C fell 28.7% to $14.28M.
DarioHealth began breaking out Commercial - B2B2C in fiscal 2024, when it brought in $20.02M. DarioHealth stopped reporting Commercial - Business-To-Business-To-Consumer ("B2B2C") as a separate revenue line after fiscal 2023, when it brought in $5.01M.
DarioHealth (DRIO) reports its revenue by product and service and by contract with customer, sales channel. In fiscal 2025, Services was its largest product and service line, bringing in $14.93M (66.8% of the total), followed by Hardware & Consumable Products at $7.43M (33.2%).
Services was DarioHealth's largest product and service line in fiscal 2025, bringing in $14.93M, or 66.8% of the $22.36M total across its two product and service lines.
Commercial - B2B2C was DarioHealth's largest revenue line in fiscal 2025, bringing in $14.28M, or 63.9% of the $22.36M total across its two revenue lines.
Hardware & Consumable Products grew faster than Services in fiscal 2025, up 8.6% from $6.84M to $7.43M. Services fell 26.1% to $14.93M.
Every figure comes from DarioHealth's annual financial filings, as reported. Each line keeps the name DarioHealth gives it, and years follow its fiscal calendar.
DarioHealth's revenue by product and service goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.